Testing Vivus' Staying Power
Executive Summary
Vivus' first-year sales of its impotence drug surpassed even its most optimistic projections. But that very success led to problems, most notably manufacturing capacity shortfalls, that threaten not just future US growth, but the drug's European launch, just when Vivus is bracing for Pfizer's market entry.